A Novel First-in-Class Microbiome-Restoration Therapy for the Prevention of Recurrence of C. diff Infection Ferring's novel first-in-class REBYOTA is indicated for the prevention of recurrence of ...

Ferring Inc. announced Health Canada has issued a Notice of Compliance, approving REBYOTA® (fecal microbiota, live), a novel first-in-class microbiome-restoration therapy indicated for the prevention ...

A real-world study of patients with Clostridioides difficile infection (CDI) in Australia over 10 years shows that fecal ...

Patients with immunocompromised status and prior hospitalization for C diff were among those at increased risk of antibiotic ...

Tim Story, a Mississippi football coach, was given months to live after late-stage colon cancer. He enrolled in a clinical ...

A group of gut bacteria successfully hindered recurrent Clostridium difficile infection in mice, offering alternative therapeutic strategies to antibiotics and fecal transplant. Sneha Khedkar is an ...

To supplement the strain library, CMIT-affiliated researchers have traveled to many corners of the globe to collect stool samples from far-flung indigenous populations, an effort that continues to ...

While fecal microbiota transplantation has shown promise in treating C. diff, the effectiveness of orally administered microbiome therapeutics has not been well-studied in recurrent infections.

When patients with Clostridium difficile colitis do not respond to ... to the impractical (fecal transplant) to the unavailable (vaccination). But when patients have severe disease — as defined ...